Patients in CR at day +100 after HDT/ASCT: disease features with a significant effect on TTP or OS (univariate and multivariate analyses)
| . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| TTP . | OS . | TTP . | OS . | |||||
| 3 y, % . | P . | 3 y, % . | P . | HR . | P . | HR . | P . | |
| Induction | .9 | .4 | — | — | — | — | ||
| VBMCP/VBAD | 72 | 90 | ||||||
| VBMCP/VBAD/ bortezomib | 79 | 100 | ||||||
| TD | 80 | 100 | ||||||
| VTD | 79 | 92 | ||||||
| ISS disease stage | .5 | .08 | — | — | 1.0 | .9 | ||
| I or II | 77 | 95 | ||||||
| III | 60 | 75 | ||||||
| Age, y | .5 | .06 | — | — | 3.5 | .03 | ||
| Younger than 60 | 77 | 90 | ||||||
| ≥ 60 | 70 | 90 | ||||||
| Hemoglobin, g/L | .07 | .01 | 1.2 | .6 | 2.0 | .2 | ||
| > 100 | 78 | 94 | ||||||
| ≤ 100 | 69 | 83 | ||||||
| Serum albumin, g/L | .3 | .2 | — | — | — | — | ||
| > 35 | 79 | 90 | ||||||
| ≤ 35 | 53 | 87 | ||||||
| Serum β2-microglobulin, mg/L | .4 | .7 | — | — | — | — | ||
| ≤ 3.5 | 76 | 93 | ||||||
| > 3.5 | 64 | 81 | ||||||
| BM PCs, % | .2 | .9 | — | — | — | — | ||
| < 30 | 79 | 94 | ||||||
| ≥ 30 | 66 | 93 | ||||||
| % PCs in S phase | .2 | .1 | — | — | — | — | ||
| < 2 | 86 | 98 | ||||||
| ≥ 2 | 73 | 91 | ||||||
| Interphase FISH cytogenetics | < 001 | .07 | 6.4 | < .001 | 4.3 | .03 | ||
| Standard risk | 80 | 96 | ||||||
| High risk* | 40 | 73 | ||||||
| Response before HDT/ASCT | .1 | .8 | — | — | — | — | ||
| CR | 75 | 93 | ||||||
| No CR | 68 | 89 | ||||||
| MRD status by MFC | < .001 | .001 | 7.7 | < .001 | 6.6 | .003 | ||
| Immunophenotypic CR | 86 | 98 | ||||||
| No immunophenotypic CR | 58 | 80 | ||||||
| Maintenance | .006 | .08 | 5.1 | .1 | 1.2 | .9 | ||
| Interferon/prednisone | 74 | 89 | ||||||
| Interferon-α2b | 60 | 87 | ||||||
| Thalidomide | 87 | 94 | ||||||
| Bortezomib/thalidomide | 84 | 100 | ||||||
| . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| TTP . | OS . | TTP . | OS . | |||||
| 3 y, % . | P . | 3 y, % . | P . | HR . | P . | HR . | P . | |
| Induction | .9 | .4 | — | — | — | — | ||
| VBMCP/VBAD | 72 | 90 | ||||||
| VBMCP/VBAD/ bortezomib | 79 | 100 | ||||||
| TD | 80 | 100 | ||||||
| VTD | 79 | 92 | ||||||
| ISS disease stage | .5 | .08 | — | — | 1.0 | .9 | ||
| I or II | 77 | 95 | ||||||
| III | 60 | 75 | ||||||
| Age, y | .5 | .06 | — | — | 3.5 | .03 | ||
| Younger than 60 | 77 | 90 | ||||||
| ≥ 60 | 70 | 90 | ||||||
| Hemoglobin, g/L | .07 | .01 | 1.2 | .6 | 2.0 | .2 | ||
| > 100 | 78 | 94 | ||||||
| ≤ 100 | 69 | 83 | ||||||
| Serum albumin, g/L | .3 | .2 | — | — | — | — | ||
| > 35 | 79 | 90 | ||||||
| ≤ 35 | 53 | 87 | ||||||
| Serum β2-microglobulin, mg/L | .4 | .7 | — | — | — | — | ||
| ≤ 3.5 | 76 | 93 | ||||||
| > 3.5 | 64 | 81 | ||||||
| BM PCs, % | .2 | .9 | — | — | — | — | ||
| < 30 | 79 | 94 | ||||||
| ≥ 30 | 66 | 93 | ||||||
| % PCs in S phase | .2 | .1 | — | — | — | — | ||
| < 2 | 86 | 98 | ||||||
| ≥ 2 | 73 | 91 | ||||||
| Interphase FISH cytogenetics | < 001 | .07 | 6.4 | < .001 | 4.3 | .03 | ||
| Standard risk | 80 | 96 | ||||||
| High risk* | 40 | 73 | ||||||
| Response before HDT/ASCT | .1 | .8 | — | — | — | — | ||
| CR | 75 | 93 | ||||||
| No CR | 68 | 89 | ||||||
| MRD status by MFC | < .001 | .001 | 7.7 | < .001 | 6.6 | .003 | ||
| Immunophenotypic CR | 86 | 98 | ||||||
| No immunophenotypic CR | 58 | 80 | ||||||
| Maintenance | .006 | .08 | 5.1 | .1 | 1.2 | .9 | ||
| Interferon/prednisone | 74 | 89 | ||||||
| Interferon-α2b | 60 | 87 | ||||||
| Thalidomide | 87 | 94 | ||||||
| Bortezomib/thalidomide | 84 | 100 | ||||||
VBMCP/VBAD indicates vincristine, carmustine (BCNU), melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, and dexamethasone; TD, thalidomide, dexamethasone; VTD, bortezomib, thalidomide, dexamethasone; ISS, International Staging System; and —, not included in the multivariate analysis.
High-risk cytogenetics includes any t(4;14), t(14;16), or del(17p); standard-risk cytogenetics includes all other cases.